Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
-0.49%
)
US TECH 100
26,375.20
(
0.28%
)
Dow Jones
49,141.93
(
-0.34%
)
Brent Oil
107.50
(
2.95%
)
Bitcoin
77,686.56
(
1.76%
)
News Focus
News Focus
Post# of 823450
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biosectinvestor

Send PM Follow Ignore
Followers 200
Posts 25597
Boards Moderated 0
Alias Born 04/03/2010

biosectinvestor

Re: exwannabe post# 512490

Friday, 09/09/2022 10:19:35 PM

Friday, September 09, 2022 10:19:35 PM

Post# of 823450
They have approximately the anticipated number of treatment arm patients, as I recall, just not the placebo patients, which I have explained, suggests that enrolling more placebo patients and delaying their care when there is no placebo arm because of the crossover and also given the issues around PFS, would be unethical. Any difference you might suggest would likely be the result of other factors, but I think your take is flatly incorrect.

I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News